Transforming Bladder Cancer Treatment: The Rise of Immunotherapy in Community Oncology Practices

This insight piece explores how treatment patterns in bladder cancer have shifted as immunotherapy options have expanded in community oncology. You’ll learn how combination regimens such as enfortumab vedotin–pembrolizumab have become more widely used, what real world data shows about changes in first line treatment choices, and how duration on therapy differs across approaches. It offers a real-world look at how community providers are adapting to new evidence and incorporating emerging options into care.